NCT06648057 2026-03-18Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus PembrolizumabCHA UniversityRecruiting100 enrolled
NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT04430738 2026-02-24Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen Inc.Phase 2 Active not recruiting40 enrolled 67 charts
NCT06282575 2026-02-24Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerJazz PharmaceuticalsPhase 3 Recruiting286 enrolled
NCT05194072 2026-01-09A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsSeagen Inc.Phase 1 Terminated250 enrolled